References
- Yotebieng M, Van Rie A, Moultrie H et al. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS24, 1341–1349 (2010).
- Joint United Nations Programme on HIV/AIDS and World Health Organization. AIDS Epidemic Update 2009. Geneva, Switzerland (2009).
- Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F; Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet364(9441), 1236–1243 (2004).
- Martinson NA, Moultrie H, van Niekerk R et al. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int. J. Tuberc. Dis.13(7), 862–867 (2009).
- Mofenson LM, Oleske J, Serchuck L, Van Dyke R, Wilfert C. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm. Rep.53, 1–92 (2004).
- World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a Public Health Approach 2002. World Health Organization, Geneva, Switzerland (2002).
- Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med.359, 2233–2244 (2008).
- Breen RA, Miller RF, Gorsuch T et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J. Infect. Dis.193, 1437–1440 (2006).
- World Health Organization. TB/HIV Research Priorities in Resource-Limited Settings. Report of an Expert Consultation February. World Health Organization, Geneva, Switzerland (2005).
- World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. World Health Organization, Geneva, Switzerland (2006).
- Abdool Karim SS, Naidoo R, Grobler A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med.362, 697–706. (2010).
- Blanc FX, Sok T, Laureillard D et al. Significant enhancement in survival with early (2 weeks) vs late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. Presented at: XVIII International AIDS conference. Vienna, Austria, 18–23 July 2010 (Abstract THLBB1 Late breaker Teack B-1).
- Torok ME, Yen NTB, Chau TTH, Mai NTH, Phu NH. Randomised controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculosis meningitis. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
- Lawn SD, Wilkinson RJ, Lipman MCI, Wood R. Immune reconstitution and ‘unmasking’ of tuberculosis during antiretroviral therapy. Am. J. Respir. Crit. Care Med.177(7), 680–685 (2008).
- Hatherill M, Hanslo M, Hawkridge T et al. Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa. Bull. World Health Organ.88, 312–320 (2010).
- Zolopa A, Andersen J, Powderly W et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE4, e5575 (2009).
Websites
- Randomized controlled trial to determine the optimal timing for HAART initiation among HIV–TB co-infection. ACTG 5221 www.cidrz.org/projects/actg_5221 (Accessed 30 July 2010)
- South African National Treatment Guidelines 2004, National Department of Health www.hst.org.za/uploads/files/sa_ART_Guidelines1.pdf (Accessed 1 August 2010)